Introduction
============

Platinum-based chemotherapy, in combination with other anticancer drugs, is one of the most potent and widely used chemotherapeutic treatments. Platinum analogues display clinical activity against a broad spectrum of malignancies, including testis, ovary, head, neck and lung cancers. However, one of the major limitations of the use of platinum-based chemotherapy is that the disease almost invariably progresses to a platinum-resistant state, primarily in lung and ovarian cancers [@B1], [@B2]. In fact, it is common to find many studies enclosing both pathologies from researchers working in the field of drug-resistance [@B3]-[@B6]. A number of events have been proposed to explain the phenomenon of cisplatin resistance in cancer, including alterations in the epigenetic regulatory machinery, such as the silencing of gene expression through promoter methylation [@B7], [@B8]. This process has been also reported in the silencing of regulatory regions of tumor suppressor microRNAs (miRNAs), thereby increasing the expression of their target genes in cancer [@B9]. In fact, miRNAs are the most recently discovered mechanism of epigenetic inheritance that acting with messenger RNA can alter gene expression status [@B10]. miRNAs were first related to cancer in 2002; those that were downregulated were defined as tumor suppressor miRNAs, such as the miR-15a/16-1 cluster in chronic lymphocytic leukemia [@B11]. The gain or loss of these miRNAs can increase or decrease the activity of several signaling pathways in cancer cells [@B12]. For instance, a number of miRNAs are regulated by c-MYC, an oncogene that codes for a transcription factor involved in cancer and regulates processes such as cell cycle progression (miR-17, let-7), inhibition of apoptosis (miR-19a, miR-26a) and metastasis (miR-9) [@B13]. Moreover, miRNAs can regulate the action of DNA-methyltransferases, which has been associated with tumorigenesis in mice injected with lung cancer cell lines [@B14]. DNA methylation is one of the epigenetic regulators of miRNA expression and therefore, might be also responsible for the development of resistance to chemotherapy. The silencing though DNA methylation can be reverted by combination of demethylating drugs and histone deacetylase (HDAC) inhibitors such as 5 Aza-2deoxycytidine (5Aza-dC) and Trichostatine A (TSA). Both drugs act in synergy by depleting methyltransferase activity [@B15] and reversing the formation of transcriptionally repressive chromatin structure [@B16], Strategy previously described in many tumor types [@B17], [@B18]. However, our understanding of the regulation of miRNA expression and their role in chemoresistance is still poor [@B19]. In this study, we aimed to gain insight into the role of miRNA epigenetic regulation by DNA methylation over the response to cisplatin in cancer. We compared the global miRNA and mRNA expression profiles between sensitive/resistant-paired cancer cell lines under reactivation treatment and we analyzed whether those changes were due to DNA hypermethylation by further functional validation in different cell lines and cohorts of ovarian cancer patients.

Materials and Methods
=====================

Cell culture, treatments and viability to CDDP
----------------------------------------------

Fifteen human cancer cell lines were purchased from ATCC (Manassas, VA) or ECACC (Sigma-Aldrich, Spain) and cultured as recommended. The CDDP-resistant variants A2780R and OVCAR3R were selected after a final exposure to 0.5 and 0.05 μg/ml cisplatin, respectively (Farma Ferrer, Spain), as previously described for H23R and H460R variants [@B20]. The additional 11 human cell lines, PC-3, LNCAP, H727, HT29, A549, BT474, LoVo, IMIM-PC-2, SKOV3, SW780 and IMR90, were used for further validations. For viability assays cells were treated with increasing doses of CDDP as described [@B21]. The epigenetic reactivation drugs 5Aza-2deoxycytidine (5Aza-dC) and trichostatin A (TSA) (Sigma-Aldrich, Spain) were used at 5µM and at 300nM respectively as described [@B22]. Cell authentication and treatments are described in [Supplementary Material](#SM0){ref-type="supplementary-material"} and Methods and Supplementary Table [1](#SM0){ref-type="supplementary-material"}.

Clinical sample and data collection
-----------------------------------

Formalin-Fixed Paraffin embedded (FFPE) and fresh-frozen ovarian cancer samples were collected from untreated patients and associated clinical data were obtained from Hospital Parc de Salut Mar (83 patients) and Biobank of IDIS-CHUS-HULP (55 patients) representing the most frequent ovarian cancer subtypes; all the patients underwent chemotherapy treatment after sample collection. Seven patients were also selected from stage III/IV patients from Hospital Madrid Clara Campal with a platinum treatment response classified as refractory or resistant. In addition, 22 high-grade serous carcinoma (HGSOC), were obtained from the National Cancer Research Centre (CNIO) biobank in collaboration with Dr. J. Benitez, from a previously reported cohort of patients [@B23]. We also collected 10 normal ovarian samples from patients who had undergone a sex reassignment surgery or tubal ligation and 10 peripheral blood mononuclear cells (PBMCs) to discard genomic imprinting. Follow-up was conducted according to the criteria of the medical oncology divisions from each institution. All the samples were processed following the standard operating procedures with the appropriate approval of the Human Research Ethics Committees at each contributing center, including informed consent within the context of research. Clinical, pathological and therapeutic data were recorded by an independent observer, and a blind statistical analysis was performed on these data.

RNA extraction and miRNA/mRNA array preprocessing
-------------------------------------------------

RNA extraction, assessment of quality and hybridization into Agilent platforms for microRNA and mRNA microarrays and data normalization is deeply described in [Supplementary Materials](#SM0){ref-type="supplementary-material"} and Methods. The criteria used for filtering the miRNA/mRNA data were according to the packages recommended by Agilent, and were analyzed by two independent bioinformaticians. miRNA/mRNA experiments had an average expression over the 20th percentile of all average expressions and changed across the different conditions (i.e. with a coefficient of variation \[CV\] \>5% across all samples). Global data were combined to identify those miRNAs, with inhibited expression after cisplatin treatment that were re-expressed after epigenetic reactivation, together with those genes that have *in silico* mRNA complementary sequences and opposite expression. Genes were considered as targets if selected with at least one of the 10 methods described by Alexiou *et al* [@B24]. For the inverse expression profiles, only those pairs (miRNA, gene) with a negative Spearman correlation coefficient and a p-value for this correlation \<0.1 were considered as potential targets. The databases GeneCard (<http://www.genecards.org>) miRBase ([www.mirbase.org](http://www.mirbase.org)), mirwalk ([www.umm.uni-heidelberg.de/apps/zmf/mirwalk](http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk)) and Web gestalt ([www.bioinfo.vanderbilt.edu/webgestalt](http://www.bioinfo.vanderbilt.edu/webgestalt)) were used for bioinformatics analysis [@B25]-[@B27]. (GEO reference: GSE84201).

RNA isolation and quantitative RT-PCR
-------------------------------------

Total RNA was retrotranscribed and quantitative RT-PCR analysis were performed as previously described [@B20], [@B22]. Samples were analyzed in triplicate using the HT7900Real-Time PCR system (Applied Biosystems, USA), and relative expression levels were calculated according to the comparative threshold cycle method (2^-ΔΔCt^) using RNU48 or RNU6B as an endogenous control miRNAs and GADPH or β-actin as an endogenous control genes. Primers and probes for expression analysis were purchased from Applied Biosystems. miRNAs probes are detailed in Supplementary Table [2](#SM0){ref-type="supplementary-material"}. Probes for gene expression are as follows: *MAFG*: Hs 01034678_g1; ELK1: Hs 00901847_m1; *MAPKAP1*: Hs 01118091_m1; *ABCA1*: Hs 01059118_m1; GADPH: Hs03929097_g1; β-actin: Hs99999903_m1. Data are presented as the "change of expression in number of times" (Log10-RQ) and the error bars are expressed as the maximum estimate (RQmax) and the minimum estimate (RQmin) expression levels, representing the standard deviation of the average expression level RQ. miRNAs from human HEK-293T cell line were isolated using the miRNeasy kit (Quiagen, USA) and miR-7 expression analysis was carried out as described before, using RNU48 as endogenous control and the experimental groups transfected with 3\'-UTR plasmid control and miR-NC as calibrators.

Site-directed mutagenesis assay
-------------------------------

The full length MAFG-3\'-UTR sequence (NM_002359.3 OriGene, USA) was used as a template to generate the mutants MAFG 3´UTR. Two different regions were identified by more than six bioinformatical algorithms as seed region of miR-7 binding site. Seven nucleotides within each seed region were mutated. Site-directed mutagenesis was carried out with QuikChange lightning site-directed mutagenesis kit (Stratagene, USA) according to the manufacturer\'s instructions. The presence of both mutated seed regions and the integrity of the remaining MAFG 3ÚTR sequence of all constructs were validated by Sanger sequencing. The primers designed to introduce mutations were for Region2: Fw-5\'-caagtaaaccatgatatat**agtgcta**cttccaccttaactttgcc-3\'; Rv-5\'-ggcaaagttaaggtggaag**tagcact**atatatcatggtttacttg-3\'; and for Region8: Fw-5\'-ggccaagcgttccctggcc**agtgcta**tctggcctcagctttgttc-3\', Rv-5\'-gaacaaagctgaggccaga**tagcact**ggccagggaacgcttggcc-3\'.

Cell Transfection and lentiviral transduction
---------------------------------------------

miR-7 overexpression and silencing: Cell lines were seeded at 500,000 cells/p60 plate, then transfected with 40 or 50 nM of miR-7 precursor, anti-miR-7 or negative controls (AM17100, AM 17110, AM10047 and AM17010 Ambion, USA) and using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer\'s protocol.

### Luciferase assay

HEK-293T cells were transfected with MAFG-3\'-UTR, MAFG-3\'-mutated-UTR, ABCA1-3\'-UTR or ELK-1-3\'-UTR plasmids (OriGene, USA), and PremiR-hsa-miR-7 or Negative Control as described above. Luminiscence was assayed 24 hours later using the Kit Renilla Luciferase Assay System (Promega, USA), according to the manufacturer\'s instructions. Results were normalized to the Renilla luminescence from the same vector and shown as the ratio between the various treatments and cells transfected with control vector.

### cDNA plasmids transfection

A Myc-DDK-tagged ORF clone of *MAFG*, *ELK-1* or *ABCA1* and the negative control pCMV6 were used for in transient transfection (OriGene, USA). H23 and A2780 cells were plated onto 60-mm dishes at 6x105 cells/dish and transfected with a negative control, *MAFG*, *ELK-1* or *ABCA1* vectors (IDs: RC221486; RC208921 and RC221861) using jet-PEI DNA Transfection Reagent (PolyPlus Transfection, USA). For stable overexpression, lentiviruses carrying *ELK-1* cDNA (Applied Biological Materials, Canada) were obtained by cotransfecting 15 μg of the specific lentiviral vector (pGIPZ-nonsilencing or pLenti-GIII-CMV-h*ELK-1*-GFP-2A-Puro) and 5 μg of each packaging vector (pCD-NL-BH and pMD2-VSV-G) in 10 million HEK 293T cells using Lipofectamine 2000 (Invitrogen, USA). Supernatants were taken at 48 hours posttransfection. A2780S cells were plated onto 60-mm dishes at 1x105 cells/dish and transduced with supernatant carrying nonsilencing or *ELK-1* lentivirus, and polybrene was added (5 μg/ml).

Transfection efficacy was measured by qRT-PCR, using the sensitive cell line transfected with the negative control as a calibrator. Two independent experiments were performed in quadruplicate.

Epigenetic validation: CpG island identification, DNA extraction, bisulfite modification, bisulfite sequencing and methylation-specific PCR
-------------------------------------------------------------------------------------------------------------------------------------------

The occurrence of CpG islands (CGIs) encompassing microRNA genes or being located nearby as well as the identification of repetitive elements were assessed using various programs for CGI-revealing, listed and described in [Supplementary Material](#SM0){ref-type="supplementary-material"} and Methods. The possible gene in which the miRNA was encoded was also analyzed, searching for the presence of 5´ CGIs located in the transcriptional site. The DNA from a total of 151 samples, including tumors, controls and cultured cell was isolated, bisulfite modified and used for BS, as previously described [@B22]. Primers design, PCR and electrophoresis conditions are detailed in [Supplementary Material](#SM0){ref-type="supplementary-material"} and Methods. Primers are listed in Supplementary Table [3](#SM0){ref-type="supplementary-material"}. For BS, we prefer direct sequencing, to subcloning of a mixed population of alleles to avoid potential cloning efficiency bias [@B28] and artifact [@B29].

Western blot analysis
---------------------

Cell lines were cultured at a density of 600,000 cells per 60-mm plate, shifted into medium containing 10% fetal bovine serum for 24 h and 72 h. Twenty micrograms (20 μg) of whole-cell extracts were subjected to Western blot, performed as previously described [@B30]. The primary antibodies employed were the c-Myc-A14 (Santa Cruz, USA) and β-tubulin (Sigma, Spain) antibodies.

Statistical analysis
--------------------

For the identification of differentially expressed miRNAs and genes from the microarray data, we used linear models [@B31] as implemented in the Limma Bioconductor package. The fixed effects were the origin of the tissue (lung/ovarian), the cell line (H460, H23, OVCAR3, A2780) and the condition (sensitive, resistant, resistant treated). The replicate is the random effect. To identify the downregulated miRNAs in resistant cells and their opposite expressed target genes, we performed the following contrasts for all the tissues (lung and ovarian) or for each tissue origin (lung or ovarian): resistant vs. sensitive and resistant-treated vs. resistant.

We then selected the candidates that fulfill the following conditions in at least 2 of the 4 cell lines interrogated: Log2(R/S) \<0 AND Log2 (RT/R) \>0; RvsS or RTvsR statistically different p\<0.05. As a statistical method we used the unpaired T-test algorithm with Benjamini Hochberg (BH) as the FDR correction method for multiple testing corrections with statistical significance of p\<0.1 in the miRNA approach and p\<0.05 in the gene approach as an adjusted p-value.

Patient\'s clinical characteristics were described for the complete series with mean and standard deviation values or relative frequencies. The data were stratified for patients carrying methylated or unmethylated DNA, and their distributions compared with the chi-squared test or Fisher\'s exact test for qualitative variables, and Student\'s t test or the Wilcoxon-Mann-Whitney test (non-normal distribution) for quantitative variables. Overall survival and Progression free survival (PFS) were estimated according to the Kaplan-Meier method and compared between groups by means of the log-rank test. All the p-values were two-sided, and the type I error was set at 5 percent. Statistical analyses were performed using Stata 10 software.

Results
=======

Establishment of ovarian human cancer cell lines resistant to CDDP
------------------------------------------------------------------

We have established 2 ovarian cancer cell lines resistant to CDDP, A2780-R and OVCAR3-R, that showed approximately three times more drug resistance than the paired parental cell line A2780 and OVCAR3 (3.00 and 2.96 Resistant-Index (RI); *p\<0.001*) and a similar CDDP RI to H23R and H460R NSCLC cancer cells, that we established previously [@B20], (3.35 and 2.50 respectively; *p*\<0.001) (Figure [2](#F2){ref-type="fig"}A and Supplementary Figure [1](#SM0){ref-type="supplementary-material"}A).

Identification of candidate miRNAs
----------------------------------

As a first step to identify candidate miRNAs under epigenetic regulation and involved in the CDDP response, we searched for miRNAs showing a decrease of the expression in R versus S cells and a recovered expression after epigenetic reactivation-treated (RT) versus R cells. First, 87 miRNAs identified on the expression arrays showed a significant expression change (*p\<0.05*) in at least one of the following conditions: R \< S or RT *\>* R; while 28 changed their expression with a *p-value* adj\<0.1 simultaneously in both situations. By analyzing the concurrence of CGIs with the characteristics described by Takai and Jones [@B32], candidates were reduced to 10 encompassing microRNA genes or being located nearby (less than 2000 bp 5´-upstream), together with the analysis of the presence of CGIs in the gene promoter region in which the miRNA is encoded. After a pair-base-complementarity analysis *in silico* between miRNA and the candidate target genes that showed an opposite expression profiles (Supplementary Database Information); we made a functional web-based enrichment analysis with the selected genes by GOTM. This approach identified 7 miRNAs which potential target genes were involved in tumor progression: miR-7, miR-132, miR-335, miR-148a, miR-10a, miR-124 and miR-9 (Figure [1](#F1){ref-type="fig"} and Supplementary Table [4](#SM0){ref-type="supplementary-material"}). Mature miR-7 is generated from three different miRNA precursors in the human genome, miR-7-1, miR-7-2, and miR-7-3; we assumed expression changes were tightly associated to miR-7-3 (hereafter called miR-7) as no changes were identified on miR-7-1 and miR-7-2 probes represented in the array and it is the only precursor that presents two CGIs surrounding its genome location. We also found that some of the miRNAs showing the strongest upregulation were located at the C19MC cluster, previously linked with carcinogenesis [@B33]. It presents a CGI located about 17kb from the first miRNA [@B34] that was included to analyze its potential epigenetic regulation in drug resistance.

miRNA-7 as potential chemoresistance candidate under epigenetic regulation
--------------------------------------------------------------------------

Firstly, we validated the expression profile of the 3 experimental conditions (S, R and RT) by qRT-PCR assay confirming the results from the microarray analysis for all 7 miRNAs in at least one of the four cell lines analyzed. Three of the seven miRNAs showed changes in their expression according to the microarray data in A2780 cells: miR-7, miR-132 and miR-10a, whereas no significant changes in expression between S and R cells were found for miR-124 (Figure [2](#F2){ref-type="fig"}B). The cell line OVCAR3 showed changes in miR-132 and -124, according to the array data. Although both increased expression in RT, no differences between S and R were reported (Figure [2](#F2){ref-type="fig"}C). For the lung cancer model, 6 miRNAs in H23 cells and 2 miRNAs in H460 cells miRNAs were fully validated (Supplementary figure [1](#SM0){ref-type="supplementary-material"}B-C).

miR-132, miR-148a miR-335, and miR-7, were validated in at least 2 cell lines and further selected for epigenetic validation by bisulfite sequencing (BS), together with the C19MC cluster\'s CGI. This cluster is on the long arm of chromosome 19 and has a CGI of 2255 bp from which we analyzed 394 bp that comprises the area with the highest density of CG positions in H23, H460, A2780 and OVCAR3 cell lines. We also tested DNA from normal tissues from lung (LC), ovary (OC) and PMBCs to discard imprinting. All analyzed CpG positions were densely methylated (Supplementary Figure [2](#SM0){ref-type="supplementary-material"}A), confirming a possible role in embryonic development as described [@B35], [@B36], but excluding a relation between acquisition of DNA hypermethylation and drug-response. Referred to miR-132, the area analyzed was 866 bp in length, at a CGI comprising -1847/+667bp at the short arm of chromosome 17. miR-148a is located on the short arm of chromosome 7, with a nearby CGI of 1663, located 137 bp upstream from the miRNA. A 560 bp area of the CGI was analyzed. No methylation was found for both miRNAs either on the tumor cell lines or controls samples analyzed (Supplementary Figure [2](#SM0){ref-type="supplementary-material"}B and 2C). miR-335 is located on the long arm of chromosome 7, on the second intron of the MEST002 gene transcript. A 1123 bp CGI is located in the promoter region of this transcript. We analyzed a fragment of 528 bp initially in the H23S/R, H460S/R cells and LC. The results showed methylation only in H460S/R subtypes. We extended the analysis to the additional cell lines LoVo, OVCAR3 and PC-3, and control samples, and no methylation was found in any of them (Supplementary Figure [2](#SM0){ref-type="supplementary-material"}D). Pairs of primers are listed in Supplementary Table [3](#SM0){ref-type="supplementary-material"}.

miR-7 is located on the short arm of chromosome 19, with 2 potential regulatory CGIs: one located 861 bp before the first nucleotide of the miRNA sequence with a length of 667 bp; the second has an extension of 269 bp and comprises the miRNA sequence (Figure [3](#F3){ref-type="fig"}). Two overlapping pairs of primers were used to analyze the first CGI, covering 776 bp, which included the entire CGI and adjacent areas (Supplementary Table [3](#SM0){ref-type="supplementary-material"}). The analysis was performed on the ovarian cancer cells A2780S and A2780R. We found the presence of methylation specifically in the resistant cells. The specific aberrant methylation of miR-7 in resistance was confirmed in H23R cells as well as in the cisplatin resistant cell lines IMIM-PC2 and LoVo, which present an IC~50~ over 2µg/ml CDDP (Supplementary Figure [3](#SM0){ref-type="supplementary-material"}). OC and LC were used as controls as well as nine additional tumor cell lines. In fact, the sensitive subtypes and controls presented an absence of methylation. A selection of these results is shown in Figure [3](#F3){ref-type="fig"}, left. This methylation pattern was used to design the MSP primers for the analysis of FFPE primary tumors. The second CGI, was fully methylated for all the samples tested (Figure [3](#F3){ref-type="fig"}, right). Therefore, the upstream CpG island of miRNA-7 was selected for our translational approach as it was the candidate downregulated through DNA methylation in CDDP-resistant cells.

miR-7 methylation is a potential predictive biomarker for recurrence and overall survival in patients with ovarian cancer treated with platinum
-----------------------------------------------------------------------------------------------------------------------------------------------

Response rates, overall survival or progression free survival are recommended by ASCO and ESMO Clinical Practice Guidelines Committees to assess the clinical benefit of chemotherapy treatment [@B37] [@B38]. Ovarian Cancer Consensus Meeting, defines \'platinum-refractory\' as patients progressing during therapy or within 4 weeks after the last dose; \'platinum-resistant\' patients progressing within 6 months of platinum-based therapy; \'partially platinum-sensitive, patients progressing between 6 and 12 months; and \'platinum-sensitive\' patients progressing with an interval of more than 12 months (GCIG Consensus) [@B39]. Following the international guidelines, we compared the miR-7 methylation levels with OS and PFS clinical parameters on two cohorts of 83 and 55 ovarian cancer patients all of them treated with platinum. We studied the OS for all patients and the PFS in those patients that had recurred at the end of the study to analyze the relationship between platinum response and miR-7 methylation.

We observed a 29% of methylation (24 out of 83 samples) in the cohort from Hospital del Mar (Table [1](#T1){ref-type="table"}), which increased to 36% (20 out of 55) in the CHUS-HULP biobank samples, a cohort enriched in serous resistant tumors (Supplementary Table [5](#SM0){ref-type="supplementary-material"}). We also observed a higher percentage of methylation in HGSOC samples from and additional cohort of patients from the CNIO (50% methylated samples) (Supplementary Table [6](#SM0){ref-type="supplementary-material"}) and in a small group of the resistant/refractory samples from H. Madrid (57%). We also tested 10 ovarian control samples a non-tumor cell line (IMR90) and 10 PBMCs to discard imprinting and none of them were methylated (100% specificity) (Figure [4](#F4){ref-type="fig"}A). When correlating our results with the patient\'s clinical histories we obtained significant data correlating methylation and cisplatin response in the group of 33 patients that recurred. Kaplan-Meier curves show that patients relapsing before 10 months, carried preferentially methylated miR-7 tumors (80% methylated versus 14% unmethylated) (Figure [4](#F4){ref-type="fig"}B) (p=0.004). No differences were found in CDDP-refractory and resistant patients. Moreover, after 3 years of follow up over the 83 patients cohort, the overall survival was significantly higher in the group of patients with an unmethylated tumor in comparison with those with a methylated one (67% vs 35%, p=0.004) (Figure [4](#F4){ref-type="fig"}C). Similar results showing a tendency in terms of PFS and OS were also observed in the CHUS-HULP biobank cohort, although these last results were not statically significant mainly because of a size-limitation (Supplementary Figure [5](#SM0){ref-type="supplementary-material"}). Finally, we observed a decrease in the number of patients with higher ECOG status when the promoter region of miR-7 was unmethylated in the higher cohort of patients (p=0.025). Accordingly, 62.5% of the patients who harbored the methylated promoter presented ascites compared with 80% of the patients who did not develop ascites harboring an unmethylated promoter region (p=0.025) (Table [1](#T1){ref-type="table"}). Those results indicate that patients carrying an unmethylated sample tended to have less aggressive tumors, with better progression free survival after platinum treatment and overall survival rates than those who carried the methylated DNA.

*MAFG* is a direct target gene of miRNA-7
-----------------------------------------

To analyze if the methylation of miR-7 is affecting the cisplatin-cell viability through the silencing of its expression, we overexpressed miR-7 in the resistant subtypes at a final concentration of 40nM (Supplementary Figure [6](#SM0){ref-type="supplementary-material"}A). No effect on drug sensitivity was observed although efficiency of the transfection was validated by qRT-PCR, confirming the miR-7 overexpression after 72h in both cell lines (Supplementary Figure [6](#SM0){ref-type="supplementary-material"}B). The overexpression of higher concentration of pre-miR-7 (50nM) resulted in a decrease in cell viability, reaching levels of 63% and 52%, respectively, compared with their parental sensitive and resistant cell lines, transfected with the mimic negative control (Supplementary Figure [6](#SM0){ref-type="supplementary-material"}C), making unfeasible to evaluate the response to CDDP, given no representative cell population was left from the cell culture after the miR-7 precursor overexpression. Thus, to fully understand the implication of miR-7 in the development of resistance, we investigated the role of the target candidate genes that showed a significant opposite expression to miR-7 and *in silico* complementarity (Figure [1](#F1){ref-type="fig"}). Out of the 1021 genes that accomplished both conditions we selected only those that were present in A2780 and H23 cell lines and which expression increased in R compared to S and RT subtypes, with a p-value\<0.05 adjusted by FDR correction. Further functional web-based annotation using the Gene Ontology Tree Machine (GOTM) tool, grouped 149 genes in 20 significant functional groups, from which we selected *MAFG*, *MAPKAP1*, *ELK*-1 and *ABCA1* genes because of their implication in biological functions related to tumor progression (Figure [1](#F1){ref-type="fig"}, Supplementary Database information). The changes on the expression were confirmed by qRT-PCR in A2780 cells for *MAFG* and slighter but following the expected expression pattern for *ELK*-1 (Figure [5](#F5){ref-type="fig"}A) and in H23 cells for *MAFG* and *ABCA1* (Supplementary Figure [7](#SM0){ref-type="supplementary-material"}A). To probe whether *MAFG*, *ELK*-1 and/or *ABCA1* are target genes of miR-7, we overexpressed a precursor of miR-7 in the resistant subtypes to assess the changes in expression of the candidate target genes by qRT-PCR. As expected, the overexpression of miR-7 in A2780R resulted in a decrease of the expression of *MAFG* and *ELK-1*, compared with the resistant cell line transfected with the negative control (Figure [5](#F5){ref-type="fig"}B). *MAFG* regulation was also confirmed in H23R cells, in which the miR-7 precursor lead also to the decrease of the potential candidate gene *ABCA1* (Supplementary Figure [7](#SM0){ref-type="supplementary-material"}B). Efficiency of the miR-7 overexpresion was validated by qRT-PCR (Figure [5](#F5){ref-type="fig"}B and Supplementary Figure [7](#SM0){ref-type="supplementary-material"}B). A summary of this selection in shown in Supplementary Table [7](#SM0){ref-type="supplementary-material"}. Next, we cotransfected in HEK-293T cells the pre-miRNA-7 together with a luciferase reporter vector that carries the 3\'-UTR region of each candidate gene. The cotransfection with the 3\'-UTR region of *MAFG*, induced a reduction of the luciferase activity at both concentrations, 15 and 30nM of the precursor, effect that was not observed when cotransfecting 3\'-UTR regions of *ELK*-1 and *ABCA1* (Supplementary Figure [8](#SM0){ref-type="supplementary-material"}A, upper panel). Simultaneously, we confirmed through qRT-PCR that the pre-miR-7 was successfully transfected in the 293T cell line, for every experimental group (Supplementary Figure [8](#SM0){ref-type="supplementary-material"}A, lower panel). To fully confirm that *MAFG* is a target gene of miR-7, we performed directed-site mutagenesis at the predicted binding sites of miR-7 in the 3\' UTR of *MAFG*, at two different regions (Figure [6](#F6){ref-type="fig"}A), followed by luciferase reporter assays. The significant decrease of luciferase activity observed when using the WT 3\'UTR of *MAFG*, disappeared when we cotransfected pre-miR-7 with both constructs containing the mutated regions (Figure [6](#F6){ref-type="fig"}B). Moreover, to ultimately confirm this regulation, we silenced the expression of miR-7 in A2780S that resulted in increased levels of *MAFG* (Figure [6](#F6){ref-type="fig"}C). A2780 cells express miR-7 at a low level, as we can observe in Supplementary Figure [8](#SM0){ref-type="supplementary-material"}B compared with the control cell line HEK-293T, which explains the low efficiency decreasing the miR-7 levels at 48h, although it was sufficient enough to observe a strong change over *MAFG* expression.

The response to cisplatin is mediated by *MAFG* expression in human cancer cell lines
-------------------------------------------------------------------------------------

To determine if the expression of the miR-7 candidate target genes was linked to CDDP response, we conducted their *in transient* overexpression in the sensitive cells comparing their response to CDDP with their parental resistant and sensitive cell lines, both transfected with an empty vector.

*MAFG* overexpression resulted in an increase in the resistance to CDDP in A2780S cells compared with the sensitive cell line transfected with the empty vector, showing a resistance index of 1.6 (p\<0.001) (Figure [7](#F7){ref-type="fig"}A). The same effect was also confirmed in the sensitive cell line H23S reaching a similar CDDP-RI of 1.7 (p=0.01) (Supplementary Figure [9](#SM0){ref-type="supplementary-material"}A). The overexpression of *ABCA1* in H23S led to a RI of 1.5 compared with the sensitive cell line transfected with the empty vector, although it was not statistically significant (p=0.796) (Supplementary Figure [9](#SM0){ref-type="supplementary-material"}B). *ELK-1* overexpression in A2780S did not change the response to CDDP after 48 h of exposure to the drug (Figure [7](#F7){ref-type="fig"}B).

In order to confirm the efficiency of the transfection, we analyzed the mRNA and protein levels by qRT-PCR and western blot of the overexpressed genes. Results confirmed ectopic overexpression of *MAFG*, *ELK-1* and *ABCA1* at 72 h in both cell lines (H23S-*MAFG*, A2780S-*MAFG,* H23S-*ABCA1* and A2780S-*ELK-1*) with an increase of 0.2, 7, 6416 and 28-folds respectively, compared with the sensitive cell lines transfected with the control vector. No changes at protein level were found between 24 and 72 hours when analyzing MAFG and ABCA1 overexpression (Figure [7](#F7){ref-type="fig"}C and Supplementary Figure [9](#SM0){ref-type="supplementary-material"}C). However, we observed a slightly protein levels of ELK1 at 24h that was not maintained at 72 h (Figure [7](#F7){ref-type="fig"}C). Therefore, we performed the stable overexpression of *ELK-1* by transduction assays with a lentiviral vector and compare the response to CDDP with the parental-sensitive and resistant subtypes harboring a nonsilencing vector (A2780S/R -NS). As previously observed in the "in transient" experimental assays, *ELK-1* overexpression did not change the sensitivity to CDDP; however, it induced an strongly increase in the number of cells at 0 µg/ml dose, that allowed to maintain higher ratios of survival fraction when treated with CDDP, compared with the control sensitive cell line. We also confirmed the success of the overexpression by qRT-PCR (Figure [7](#F7){ref-type="fig"}D).

Discussion
==========

Epigenetic alterations by DNA methylation can reduce the expression of a number of miRNAs, altering the therapeutic response in tumor cells and contributing to the onset of more aggressive phenotypes. We intended to deepen our understanding of this aspect, identifying new miRNA-targets of promoter hypermethylation involved in the response to cisplatin, by using an experimental model of paired sensitive and CDDP-resistant tumor cell lines. We established the ovarian cancer cells A2780R and OVCAR3R, with a CDDP-RI in accordance with the previously established H23R and H460R cell lines, assuming that similar resistant events could follow [@B20]. Then, we combined an epigenetic reactivation therapy with a global transcriptomic-based strategy. The epigenetic therapy induced an expected reactivation percentage of 12% (87 of the 723 miRNAs), in accordance with published data, using the same technology and pharmacologic unmasking strategy [@B40]. The differential miRNA expression profile from sensitive, CDDP-resistant and resistant cells under epigenetic reactivation treatment was correlated with the expression of those genes from the same experimental groups that showed complementary sequences. This screening, included an ontological study of routes and processes related to tumor biology for all candidate target genes. We identified a set of 7 miRNAs containing a surrounding CGI that were complementary to target genes involved in cell growth, proliferation, cell migration, drug efflux, angiogenesis or apoptosis inhibition such *MAFG, ELK-1, RAB6B,CAMK2G, MAPKAP1, ABCA1, ABL1 or STAT3* [@B41], [@B42]. All these processes might influence the acquisition of drug-resistance in the CDDP treated cells through the potential miRNA silencing.

Changes in expression were validated for all 7 candidates, but not in all the expected paired cell lines, indicating that qRT-PCR is a valuable and necessary validation method more restrictive than microarray, that still keeps providing a powerful tool to study the involvement of a large number of miRNAs simultaneously [@B43], [@B44]. The expression changes were more significant after unmasking treatment, probably because the pharmacologic combination exerts a synergistic and specific influence in mRNA and miRNA global re-expression, as described in different tumor types [@B45]. This effect can be stronger than the silencing observed as a secondary effect of CDDP on DNA methylation.

The expression of miR-7, miR-132, miR-335 and miR-148a was validated in at least two paired cell lines. Epigenetic validation of those candidates revealed that only one miRNA from our panel, miR-7, had specific methylation in CDDP-resistance. miR-148a and miR-132 expression might be regulated by an upstream epigenetic mechanism or transcription factor reactivated by demethylation, as has been reported for other candidates [@B20], [@B22]. miR-335 epigenetic reactivation has been reported in breast cancer cells, confirming the relevance of our approach to identifying miRNAs under epigenetic regulation, although the response after platinum treatment was not studied [@B46]. We found specific methylation in both, H460S/R cells, but not in the controls and additional cell lines analyzed, suggesting that the downregulation in the resistant phenotypes is probably independent of the methylation profile. We cannot conclude that the downregulation of miR-335 is affecting the response to platinum, but the sensitivity to the drug seems not to be mediated by DNA methylation.

We focused on the epigenetic regulation of miR-7 at the upstream CpG island analyzed, as the one encompassing miR-7 showed constitutive methylation, suggesting the absence of a regulatory role, as reported for other potential regulatory CGIs [@B47]. The same methylation profile was found in ovarian, lung, colon and pancreatic cisplatin-resistant cell lines. These data suggest a potential epigenetic regulation of miR-7 at DNA methylation level for this second CGI, a relatively common event in various tumor types, which can present intrinsic resistance to CDDP by epigenetic regulation. We therefore tested the specificity of aberrant miR-7 hypermethylation as a potential epigenetic biomarker to detect the response to chemotherapy on 167 ovarian cancer patients, all of them treated with platinum-based therapy. An extensive clinical follow-up of 83 of those patients showed that those considered platinum-sensitive, harboring an unmethylated miR-7 had a better progression free survival rates than those patients with a methylated marker. These differences were not observed in platinum-resistant patients, probably because in these patients the recurrence develop in short-time periods and in a small number of cases. We confirmed the same tendency in an additional smaller cohort of 55 patients. Furthermore, our analysis indicated that those patients carrying an unmethylated marker tended to have less aggressive tumors, with three times more overall survival after platinum treatment than those who carried the methylated DNA. In addition, the methylation percentage increased in tumor grades III/IV and when analyzing high-serous samples and Platinum-refractory/resistant tumors. Thus, miR-7 methylation could play a role as a clinical tool predicting the aggressive behavior of this malignancy and the poorer response to platinum-based treatment.

We sought then to confirm the role of miR-7 in the response to CDDP, in order to explore the potential therapeutic effect of miR-7 overexpression, as it has been developed for miR-34, the first microRNA mimic to be used in clinical testing as a theranostic marker (<http://mirnatherapeutics.com>). However, the ectopically overexpression of miRNA-7 in resistant cells did not change their sensitivity to CDDP, although it induced an increase in cell mortality; probably, due to the multifactorial effect that overexpression of miRNAs may cause on the cellular processes by regulating a high number of potential candidates genes. These results validate previous studies, which have shown its possible tumor suppressor role in cancer [@B48]. Its expression has been also linked with sensitization to paclitaxel [@B49], although its regulation in this process has not being defined. miR-7 might be involved in these processes through the regulation of its target genes, whose overexpression has been found in our experimental approach. Using a transcriptomic profile together with the *in silico* assembling of sequences, we identified a group of genes candidate to be targets of miR-7 that could provide cells with the oncogenic capabilities described by Hanahan and Weinberg [@B50]. Further analysis of molecular pathways and cellular functions, led us to the selection of *MAFG*, *ELK-1*, *ABCA1* and *MAPKAP1* genes. Validation by alternative techniques and overexpression of miR-7 in the resistant cell lines, revealed that *MAFG*, *ABCA1* and *ELK-1* recovered their levels of expression after epigenetic treatment and overexpression of miR-7, thus indicating a possible regulation of these genes by the methylation of this miRNA. However, our functional studies performed with luciferase vectors carrying a mutation in the conserved miR-7 binding site, revealed that only *MAFG* seems to be a direct candidate target gene under miR-7 regulation. Moreover, the silencing of miR-7 expression resulted in increased levels of *MAFG* and its overexpression is able to strongly increase the resistance to CDDP in sensitive cells. miR-7 may be an indirect regulator of *ABCA1* and *ELK-1*, in fact, it has been reported that miR-7 could act as modulator of chemoresistance by targeting the *MRP1/ABCC1*, a member of the ABC family proteins, and being involved in lung tumorogenesis by directly regulating the *EGFR* expression [@B51]-[@B53]. Moreover, *ABCA1* upregulation has been related to the decrease in chemotherapy response in breast cancer. However, we could not find a significant increase of resistance to CDDP after*ABCA1* overexpression, possibly because of the different schema of treatment used in this study, based on sequential paclitaxel/neoadjuvant chemotherapy [@B54]. The inhibition of *ELK-1* through the drug silodosin has been reported to increase the response to cisplatin in bladder cancer cells [@B55]. Its overexpression in ovarian cancer cells did not change the sensitivity to CDDP; nevertheless, we observed an increase in the cell survival fraction. As *ELK-1* is a nuclear target of the MAP-kinases cascade and the EGFR-signaling pathway, and miR-7 is a direct regulator of EGFR gene, we believe that our results are a consequence of the highly implication of *ELK-1* in cell proliferation and apoptosis though these signaling routes [@B56].

*MAFG* is associated with detoxification in oxidative stress situations. This leads us to believe that its involvement in the acquired resistance to platinum resides in the protection it confers against free radicals generated in the cell after the administration of this drug [@B57]-[@B61]. Despite the fact that sMafs family, to which *MAFG* belongs, have been associated with cellular response, little is known about their involvement in human diseases. A number of studies have however linked these proteins with cancer, such as the study by Schembri et al. on *MAFG* regulation by miR-218 as an indicator of smoking-induced disease processes in the lungs [@B62] and the study by Yang et al. on the relationship between increased *MAFG* and growth in colon cancer cell lines through the insulin-like growth factor-I actions [@B63]. Taken together, our experimental results strongly support the direct regulation of *MAFG* through miR-7 and their involvement in the development of CDDP resistance in human tumor cells.

In the present manuscript, we introduce the epigenetic regulation of miR-7 as a mechanism involved in platinum-resistance in cancer cell lines directly regulating the action of *MAFG*, which is overexpressed in resistant phenotypes. To the best of our knowledge, this is the first report linking the regulation of *MAFG* by miRNA-7 and its role in chemotherapy response to CDDP. Moreover, miR-7 methylation arises as a potential predictive biomarker for the identification of ovarian cancer patients that may present worst response to platinum-derived treatment in terms of OS and PFS. Furthermore, this data captures the interest of researchers due to the possible role *MAFG* plays as a novel therapeutic target for platinum resistant tumors.
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![Selection of candidate miRNAs under epigenetic regulation and candidate target genes. The flowchart indicates the steps and criteria used for the selection of the final 7 candidate miRNAs under epigenetic regulation and the final 4 candidate genes under possible regulation of miR-7.](thnov07p4118g001){#F1}

![miRNA relative expression on CDDP-sensitive and -resistant ovarian cancer cell lines. (A) Viability curves showing the acquired resistance of A2780 and OVCAR3 cell lines; Cells were exposed for 72 h to each drug concentration. Data were normalized to the untreated control, which was set at 100% and represent the mean + SD of at least 3 independent experiments performed in quadruplicate at each drug concentration tested for every one cell analyzed. IC50, is the inhibitory concentration that kills 50% of the cell population. Resistant index (RI) calculated as IC50 resistant / IC50 sensitive cell line. p\<0.001 was considered as a significant change in drug sensitivity (Student\'s t-test). (B-C) Relative expression levels of the selected miRNAs measured by qRT-PCR. Data are represented in log10 scale and are expressed using the corresponding sensitive (S) line as a calibrator. Each miRNA level was normalized to RNU48 as an endogenous control. Assays were made in the ovarian cancer cell lines A2780 (B) and OVCAR3 (C) in all experimental conditions: S, R and RT. S: sensitive; R: resistant; RT: resistant treated with epigenetic reactivation drugs (5-Aza and TSA). The expression number assays for each miRNA are indicated in Supplementary Table [2](#SM0){ref-type="supplementary-material"}.](thnov07p4118g002){#F2}

![Bisulfite sequencing of miRNA-7 regulatory CGIs. Chromosomal location of miR-7 and their nearby CGIs, as well as representative images of corresponding bisulfite sequences (BS). CGIs are represented in red boxes; each CpG position is characterized by vertical black lines inside the boxes. The first nucleotide of each miRNA is indicated by +1. Facing arrows mark the primer positions used for BS. It is shown the methylation analysis of the two CGIs closely related to the encoded miR-7 region. For the first CGI, the 3 different fragments (left half of the Figure) corresponding to the most frequently methylated positions are shown. A representation of 5 of the 11 additional tumor cell lines interrogated, BT474, SKOV3, LoVo, IMIMPC2 and SW780, is also shown. All CpG positions interrogated at the second CGI were fully methylated in all the samples analyzed (right half of the Figure), as indicated by the presence of C preceding a G in the sites indicated by the asterisks. OC: ovary control; LC: lung control. Asterisks indicate methylated positions.](thnov07p4118g003){#F3}

![miRNA-7 methylation analysis in primary tumors and survival analysis. (A) Representative MSPs of miR-7 nearby CGI in DNA obtained from ovarian tumor tissues, normal ovarian tissues, non-tumor cell line and PBMCs from healthy donors. For each sample, the PCR product in the M lane was considered as the presence of methylated DNA, whereas the amplification product in the U lane was considered as the presence of unmethylated DNA. In vitro methylated DNA was used as a positive control (+). Uncropped gels of Figure [4](#F4){ref-type="fig"}a are included in Supplementary Figures (Supplementary Figure [4](#SM0){ref-type="supplementary-material"}). (B) and (C) Kaplan-Meier comparison between cisplatin treatment and miR-7 proximal island methylation in ovarian cancer patients treated with platinum in terms of progression free survival (B) and overall survival in months (C). LogRank, Breslow and Tarone-Ware tests were used for comparisons and p\<0.05 was considered as a significant change in OS or PFS. p values in (B) represent the significant difference between sensitive-unmethylated and sensitive-methylated patients](thnov07p4118g004){#F4}

![mRNAarrays data validation and effect of miRNA-7 over-expression on candidate target genes in the ovarian cancer cell line A2780. (A) Relative expression levels of the selected genes measured by qRT-PCR. Assays were made in all experimental conditions: S, R and RT. S: sensitive; R: resistant; RT: resistant treated with epigenetic reactivation drugs (5-Aza and TSA). Sensitive cells were used as calibrator. (B) Relative expression levels of *MAFG*, *ELK-1* and miR-7 measured by quantitative RT-PCR after miR-7 overexpression. The sensitive cell line transfected with the mimic negative control was used as a calibrator (S miR-NC, white). A2780R cells were transfected with same negative control (R miR-NC, stripped) or with miR-7 precursor (R miR-7, grey). For both (A) and (B), data are represented in Log10 scale obtained from the combined relative expression of 2 independent experiments measured in triplicate. Each gene expression level was normalized to *GAPDH* or *B-actin* as an endogenous control.](thnov07p4118g005){#F5}

![Site-directed mutagenesis for luciferase activity assay and effect of miR-7 silencing over MAFG expression. (A) Chromosomal localization of miR-7 predicted binding sites at 3\'UTR of MAFG. Regions 2 and 8 were identified by six or more bioinformatical algorithms. Sanger sequencing showed that the seed sequence of miR-7 was fully mutated at regions 2 and 8 of the 3\' UTR of MAFG. (B) Co-transfection of mimic miR-7 (miR-7) or mimic control (miR-NC) with the 3\' UTR of MAFG WT, mutated on region 2 (MAFG 2\*) and mutated on region 8 (MAFG 8\*). Experiments were performed at 15nM and data was analyzed after 24h of co-transfection. (Upper panel) Relative luciferase activity. The figures represent the mean ± SD of at least 3 independent experiments after data normalization with Renilla and the data from the negative control 3\'-UTR; p\<0.01 was considered as significant change in Luciferase activity (Student\'s t-test). (Lower panel) Relative miR-7 expression levels measured by qRT-PCR after co-transfection, as an internal control for the mimic transfection. Each bar represents the combined relative expression of 2 independent experiments measured in triplicate. The miR-NC co-transfected with the 3\'-UTR of each tested group was used as calibrator. (C) Relative miR-7 and *MAFG* expression levels measured by qRT-PCR after silencing of miR-7 with antago-miR in A2780S cells. Two different concentrations of Anti-miR-7 were tested, 20nM and 40 nM. Data was analyzed at 48h after transfection. Each bar represents the combined relative expression of 2 independent experiments measured in triplicate. A2780S cells transfected with the Anti-miR Negative Control was used as calibrator.](thnov07p4118g006){#F6}

![Effect of overexpression of *MAFG* and *ELK-1* on cell sensitivity to CDDP in A2780 cell lines. (A-B) Viability curves of A2780 cell lines transfected with pCMV6 (S-Ø and R-Ø) and with the overexpression vectors (S-*MAFG* and S-*ELK-1*). Each experimental group was exposed for 48 h to 6 different CDDP concentrations, and data were normalized to each untreated control, set to 100%. The data represent the mean ± SD of at least 3 independent experiments performed in quadruplicate at each drug concentration for each cell line analyzed. The CDDP-RI (Resistant Index to CDDP) was calculated as "IC50 from the R-Ø / IC50 from the S-Ø\" and "IC50 from the S-transfected with the gene / IC50 from the S-Ø" ± SD. p\<0.01 was considered as significant change in drug sensitivity (Student\'s t-test). (C) Validation of the transfection efficacy at mRNA and protein levels. Top, Relative expression levels of *MAFG* and *ELK-1* measured by quantitative RT-PCR, in the cell line A2780, represented in Log10 scale; In each experimental group, the sensitive cell line transfected with pCMV6 plasmid was used as a calibrator. Each bar represents the combined relative expression of 2 independent experiments measured in triplicate. Bottom, total cell protein (20µg) at 24 and 72 hours was subjected to WB, membranes were hybridized with antibodies against c-Myc and β-tubulin as loading control. S: Sensitive; S-G: Sensitive transfected with the gene; R: Resistant; β-tub: β-tubulin. (D) Stable overexpression of *ELK-1* in A2780S cell line. Top, Viability assay after the nonsilencing (NS) plasmid transductions (S-NS white; R-NS stripped) and overexpressing *ELK-1* plasmid (S-*ELK-1* grey). Each experimental group was exposed for 72 h to 6 different CDDP concentrations, and data were normalized to each sensitive subtype. Data represents the mean ± SD of at least 3 independent experiments performed with 4 wells at each drug concentration for each cell line analyzed. Bottom, relative *ELK-1* expression levels measured by qRT-PCR and represented in Log10 scale. The sensitive cell line with nonsilencing vector was used as a calibrator. Each bar represents the combined relative expression of 2 independent experiments measured in triplicate.](thnov07p4118g007){#F7}

###### 

Demographic table with the clinicopathological characteristics of a cohort of 83 samples from Hospital del Mar.

  Characteristics        Complete series (n=83)   Unmethylated (n=59)   Methylated (n=24)                               
  ---------------------- ------------------------ --------------------- ------------------- ------- ------ ---- ------- --
  Age (median, range)    55 (17-84)               59 (17-80)            55 (18-84)          0.880                       
  Menopausal status                                                                                             0.565   
                         Premenopausal            34                    41.0                23      39.0   11   45.8    
                         Postmenopausal           49                    59.0                36      61.0   13   54.2    
  Parity                                                                                                        0.974   
                         No                       24                    28.9                17      28.8   7    29.2    
                         Yes                      59                    71.1                42      71.2   17   70.8    
  Familiar history                                                                                              0.684   
                         No                       58                    69.9                42      71.2   16   66.7    
                         Yes                      25                    30.1                17      28.8   8    33.3    
  ECOG                                                                                                          0.025   
                         0                        21                    25.3                20      33.9   1    4.2     
                         1                        36                    43.4                22      37.3   14   58.3    
                         2                        20                    24.1                12      20.3   8    33.3    
                         3                        6                     7.2                 5       8.5    1    4.2     
  Ascites                                                                                                       0.025   
                         No                       47                    56.6                38      64.4   9    37.5    
                         Yes                      36                    43.4                21      35.6   15   62.5    
  Tumor Grade                                                                                                   0.35    
                         I                        34                    41                  27      45.8   7    29.2    
                         II                       24                    28.9                15      25.4   9    37.5    
                         III                      25                    30.1                17      28.8   8    33.3    
  Histology                                                                                                     0.883   
                         Serous                   40                    48.2                27      45.8   13   54.2    
                         Mucinous                 9                     10.8                7       11.9   2    8.3     
                         Clear cell               8                     9.6                 5       8.5    3    12.5    
                         Endometroid              4                     4.8                 3       5.1    1    4.8     
                         Others                   22                    26.5                17      28.8   5    20.8    
  Chemotherapy                                                                                                  0.956   
                         Adjuvant                 59                    71.1                43      72.9   16   66.7    
                         Neoadjuvant              6                     7.2                 3       5.1    3    12.5    
                         Metastatic               18                    21.7                13      22.0   5    20.8    
  Platinum sensitivity                                                                                          0.196   
                         Sensitive                21                    63.6                15      71.4   6    50.0    
                         Resistant                12                    36.4                6       28.6   6    50.0    
  Relapse                                                                                                       0.286   
                         No                       49                    59.0                37      62.7   12   50.0    
                         Yes                      34                    41.0                22      37.3   12   50.0    
  Death                                                                                                         0.119   
                         No                       49                    59                  38      64.4   11   45.8    
                         Yes                      34                    41                  21      35.6   13   54.2    
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